Darosa Lim Selected Research

Darosa Lim Research Topics

3	Dermatomyositis (Dermatopolymyositis) 02/2024 - 01/2020
2	Myositis (Idiopathic Inflammatory Myopathies) 03/2023 - 01/2020
1	Skin Diseases (Skin Disease) 03/2023
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Liver Diseases (Liver Disease) 01/2021
1	Xanthomatosis (Xanthoma) 01/2021
1	Hypersensitivity (Allergy) 01/2021
1	Massive Hepatic Necrosis 01/2021
1	Necrosis 01/2020
1	Lymphadenopathy 01/2020
1	Squamous Intraepithelial Lesions 01/2020
1	Exanthema (Rash) 01/2020
1	Cutaneous Lupus Erythematosus 01/2020
1	Muscular Diseases (Myopathy) 01/2020
1	Benign Familial Pemphigus (Hailey Hailey Disease) 01/2020
1	Endometrial Neoplasms (Endometrial Cancer) 01/2020
1	Muscle Weakness 01/2020
1	Dermatitis 09/2017
1	Ewing Sarcoma (Sarcoma, Ewing) 09/2017

1	pyromellitic acid dianhydride-2-hydroxyethyl methacrylate adductIBA 02/2024
1	AutoantibodiesIBA 03/2023
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021
1	Lipoprotein-XIBA 01/2021
1	LipidsIBA 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2020
1	Cidofovir (Vistide)FDA Link 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	AntibodiesIBA 01/2020
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2020
1	Naltrexone (ReVia)FDA LinkGeneric 01/2020
1	Magnesium Chloride FDA LinkGeneric 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 09/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2017
1	Vincristine (Oncovin)FDA LinkGeneric 09/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2017
1	ganitumabIBA 09/2017

2	Therapeutics 03/2023 - 01/2020
1	Aftercare (After-Treatment) 01/2020
1	Lymph Node Excision (Lymph Node Dissection) 01/2020
1	Drug Therapy (Chemotherapy) 09/2017